Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables

OBJECTIVES:Barrett's esophagus develops in 5–10% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. We have previously shown that a systematic baseline endoscopic biopsy protocol using flow cytometry with histology identifies subsets of patients with Barrett's esophagus at low and high risk for progression to cancer. In this report, we further examined cytometric variables to better define the characteristics that best enable DNA cytometry to help predict cancer outcome.METHODS:Patients were prospectively evaluated using a systematic endoscopic biopsy protocol, with baseline histological and flow cytometric measurements as predictors and with cancer as the outcome.RESULTS:A receiver operating curve analysis demonstrated that a 4N fraction cut point of 6% was optimal to discriminate cancer risk (relative risk [RR] = 11.7, 95% CI = 6.2–22). The 4N fractions of 6–15% were just as predictive of cancer as were fractions of >15%. We found that only aneuploid DNA contents of >2.7N were predictive of cancer (RR = 9.5, CI = 4.9–18), whereas those patients whose sole abnormality was an aneuploid population with DNA content of ≤2.7 had a low risk for progression. The presence of both 4N fraction of >6% and aneuploid DNA content of >2.7N was highly predictive of cancer (RR = 23, CI = 10–50). S phase was a predictor of cancer risk (RR = 2.3, CI = 1.2–4.4) but was not significant when high-grade dysplasia was accounted for.CONCLUSIONS:Flow cytometry is a useful adjunct to histology in assessing cancer risk in patients with Barrett's esophagus. Careful examination of cytometric variables revealed a better definition of those parameters that are most closely associated with increased cancer risk.

[1]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[2]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[3]  J. V. van Sandick,et al.  Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus , 2000, The Journal of pathology.

[4]  B. Reid,et al.  p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.

[5]  G. Falk,et al.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.

[6]  R. Fitzgerald,et al.  Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. , 1999, Gastroenterology.

[7]  O. Cummings,et al.  Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. , 1999, Gastrointestinal endoscopy.

[8]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[9]  D. Lieberman,et al.  The economic impact of the diagnosis of dysplasia in Barrett's esophagus , 1998, American Journal of Gastroenterology.

[10]  T. Jacks,et al.  Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption , 1998, Molecular and Cellular Biology.

[11]  J. V. van Lanschot,et al.  Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation , 1998, The Journal of pathology.

[12]  N. Shaheen,et al.  Surveillance for Barrett's esophagus: are we saving lives? , 1997, Gastroenterology.

[13]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[14]  Cameron Aj.  Barrett's esophagus: does the incidence of adenocarcinoma matter? , 1997 .

[15]  R. Margolis,et al.  Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state. , 1996, Mutation research.

[16]  Carissa A. Sanchez,et al.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[18]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[19]  R. Goyal,et al.  Prevalence of metaplasia at the gastro-oesophageal junction , 1994, The Lancet.

[20]  W. Giaretti.  A model of DNA aneuploidization and evolution in colorectal cancer. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[21]  J. Peters,et al.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[22]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[23]  V. Rusch,et al.  The management of high grade dysplasia and early cancer in Barrett's esophagus , 1994, Cancer.

[24]  J. Fraumeni,et al.  Continuing climb in rates of esophageal adenocarcinoma: an update. , 1993, JAMA.

[25]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[26]  D. Lane,et al.  Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.

[27]  B. Reid,et al.  Endoscopic Diagnosis of Esophageal Neoplasms , 1992 .

[28]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[29]  F. Ellis,et al.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.

[30]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[31]  H. Joensuu,et al.  Autolysis is a potential source of false aneuploid peaks in flow cytometric DNA histograms. , 1989, Cytometry.

[32]  S. Shackney,et al.  Model for the genetic evolution of human solid tumors. , 1989, Cancer research.

[33]  S. Shackney,et al.  Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. , 1989, Cancer research.

[34]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[35]  J. Baak,et al.  The value of morphometry and DNA flow cytometry in addition to classic prognosticators in superficial urinary bladder carcinoma. , 1989, American journal of clinical pathology.

[36]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[37]  E. Achkar,et al.  The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. , 1988, The American journal of gastroenterology.

[38]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[39]  R. deVere White,et al.  The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer. , 1988, The Journal of urology.

[40]  R. Hammer,et al.  Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. , 1987, Science.

[41]  B. Reid,et al.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.

[42]  C. Metz.  ROC Methodology in Radiologic Imaging , 1986, Investigative radiology.

[43]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[44]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[45]  M. Melamed,et al.  Accessibility of DNA in situ to various fluorochromes: relationship to chromatin changes during erythroid differentiation of Friend leukemia cells. , 1984, Cytometry.

[46]  D. Killander,et al.  Flow‐Cytometric DNA analysis in primary breast carcinomas and clinicopthological correlations , 1984 .

[47]  B. Barlogie,et al.  Characterization of hematologic malignancies by flow cytometry. , 1980, Analytical and quantitative cytology and histology.

[48]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[49]  G. Eastwood,et al.  Cell proliferation in three types of Barrett's epithelium 1 , 1980, Gut.

[50]  M. Berenson,et al.  Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). , 1978, Gastroenterology.

[51]  M. Pera.  Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[52]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.

[53]  Dawn Provenzale,et al.  Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk , 1999, American Journal of Gastroenterology.

[54]  M. Palanca-Wessels.  In vitro analysis of cultured Barrett's esophagus cells: insights into mechanisms of genomic instability and possible therapeutic strategies , 1999 .

[55]  P. Maxwell,et al.  Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. , 1998, British Journal of Cancer.

[56]  R. Sampliner,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.

[57]  P. O'Connor.  Mammalian G1 and G2 phase checkpoints. , 1997, Cancer surveys.

[58]  A. Cameron.  Barrett's esophagus: does the incidence of adenocarcinoma matter? , 1997, The American journal of gastroenterology.

[59]  O'Connor Pm.  Mammalian G1 and G2 phase checkpoints. , 1997 .

[60]  L. Wheeless,et al.  Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. , 1993, Cytometry.

[61]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[62]  G. Chejfec,et al.  Barrett's esophagus. The cytology of dysplasia in comparison to benign and malignant lesions. , 1992, Acta cytologica.

[63]  J. Cauvin,et al.  [Flow cytometric analysis of cellular DNA content in Barret's esophagus. A study of 66 cases]. , 1991, Gastroenterologie clinique et biologique.

[64]  B. Reid,et al.  Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[65]  J. Rowley,et al.  Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. , 1986, Advances in human genetics.

[66]  E. Långström,et al.  Flow-cytometric DNA analysis in primary breast carcinomas and clinicopathological correlations. , 1984, Cytometry.

[67]  John A. Swets,et al.  Evaluation of diagnostic systems : methods from signal detection theory , 1982 .